Cancer discovery
-
In the phase III PREVAIL study, taking enzalutamide prior to chemotherapy improved survival and slowed progression of metastatic castration-resistant prostate cancer. The FDA is now considering an application to expand the drug's use to the pre-chemotherapy setting.
-
The incidence of colorectal cancer in the United States dropped by 30% between 2000 and 2010 among adults ages 50 and older, according to a recent report, a decline attributed primarily to widespread screening. A new effort aims to further reduce incidence of the disease by screening 80% of adults according to current guidelines by 2018.
-
Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.